Overview

Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

Status:
Recruiting

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this phase 2 study is to evaluate the effect and the safety of the combination of ANIFROLUMAB in combination with phototherapy in adult participants with non-segmental progressive vitiligo

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Bordeaux

Collaborator:

AstraZeneca